semaglutide vs. tirzepatide
Molecular and clinical comparison between single GLP-1 receptor agonism and coordinated dual GIP/GLP-1 agonism, including head-to-head data from the pivotal SURPASS-2 NEJM trial.
semaglutide
Lyophilized 10mg vial with analytical HPLC purity ≥ 99.0%. Reference single GLP-1 receptor agonist for preclinical research.
tirzepatide
The reference dual agonist with pharmacological bias toward the GIP receptor. Demonstrated almost double the weight reduction compared to Semaglutide in the SURPASS-2 NEJM trial.
Comparative data from landmark clinical trials (NEJM).
Mechanism of Action: Single vs. Dual Incretin Agonism
Semaglutide
Semaglutide is a synthetic GLP-1 analogue featuring 94% sequence homology to native human GLP-1. It acts with high selectivity on the GLP-1 receptor (GLP-1R), delaying gastric emptying and driving glucose-dependent pancreatic beta-cell insulin secretion. It lacks measurable affinity for GIPR or GCGR, restricting its pharmacology strictly to single-receptor signaling cascades.
Tirzepatide
Tirzepatide is a 39-amino-acid synthetic peptide creating an incretin paradigm shift: synchronized agonism across both GIP and GLP-1 receptors. It exhibits native-like affinity for human GIPR (0.024 nM) while driving biased signaling at GLP-1R favoring cAMP generation over beta-arrestin recruitment. GIP receptor activation directly enhances white adipose tissue insulin sensitivity and buffering, synergizing with GLP-1 to produce superior metabolic regulation.
Head-to-Head Clinical Benchmark: The SURPASS-2 Trial (NEJM)
Semaglutide Clinical Efficacy
In the pivotal head-to-head SURPASS-2 trial published in The New England Journal of Medicine (Frias et al., 2021; 385:503-515), Semaglutide at the active 1.0 mg comparator dose yielded a mean HbA1c reduction of -1.86% and a mean body weight loss of -5.7 kg at 40 weeks.
Tirzepatide Clinical Efficacy
Within the identical SURPASS-2 trial cohort, Tirzepatide 15 mg demonstrated statistically superior glycemic efficacy (-2.30% HbA1c) and nearly doubled mean weight reduction (-11.2 kg vs -5.7 kg for Semaglutide, p < 0.001), establishing the indisputable biological advantage of dual incretin agonism.
Pharmacokinetics, Acylation Profiles & Tolerability
Both peptides leverage fatty diacid acylation to extend circulating half-life via reversible human serum albumin binding. Semaglutide features a C18 fatty diacid acylated at Lys26 via an AEEA-AEEA-gamma-Glu linker, granting an elimination half-life of approximately 7 days. Tirzepatide utilizes a C20 eicosanedioic diacid moiety at Lys20 with a gamma-glutamyl linker, achieving a half-life of approximately 5 days. Notably, GIP co-activation in Tirzepatide buffers against the intense gastrointestinal nausea signals triggered by pure high-dose GLP-1 receptor stimulation.
Pharmacological and analytical specifications.
| PARAMETER | SEMAGLUTIDE (NN9535) | TIRZEPATIDE (LY3298176) |
|---|---|---|
| Agonist Class | Single Receptor Agonist (GLP-1R) | Dual Agonist (GIPR / GLP-1R) |
| Target Receptors | GLP-1R | GIPR, GLP-1R |
| In-Vitro Binding Affinity (Human EC50) | GLP-1R: 0.38 nM | GIPR: Inactivo (>1000 nM) | GIPR: 0.024 nM | GLP-1R: 0.24 nM |
| Adipose Tissue Action & Lipolysis | Indirect (secondary to hypothalamic calorie deficit) | Direct via GIPR (insulin sensitization and FA buffering) |
| Weight Loss Benchmark (Monotherapy) | -14.9% at 68 weeks (STEP-1 NEJM, 2.4 mg) | -20.9% at 72 weeks (SURMOUNT-1 NEJM, 15 mg) |
| Direct Head-to-Head Trial (SURPASS-2) | -5.7 kg weight loss | -1.86% HbA1c (1.0 mg) | -11.2 kg weight loss | -2.30% HbA1c (15 mg) |
| Plasma Elimination Half-Life (t1/2) | ~7 days (~165 hours) | ~5 days (~120 hours) |
| Peptide Sequence Length | 31 amino acids (C18 diacid acylated at Lys26) | 39 amino acids (C20 diacid acylated at Lys20) |
| Gastrointestinal Tolerability Profile | Common dose-dependent transient nausea during escalation | GIP agonism counteracts central GLP-1 emetic signals |
| HPLC / MS Purity Standard | ≥ 99.0% (Liofilizado analítico verificado por lote) | ≥ 99.4% (Liofilizado analítico verificado por lote) |
| Reconstitution Vehicle | Sterile Bacteriostatic Water (0.9% Benzyl Alcohol) | Sterile Bacteriostatic Water (0.9% Benzyl Alcohol) |
| Storage (Lyophilized Powder) | -20°C (24 meses de estabilidad) | -20°C (24 meses de estabilidad) |
| Storage (Reconstituted Solution) | 2°C – 8°C (hasta 28 días protegido de luz) | 2°C – 8°C (hasta 28 días protegido de luz) |
| Availability & Dispatch | In stock in Spain · Express 24-72h EU shipping (no customs) | In stock in Spain · Express 24-72h EU shipping (no customs) |
| Legal Classification | Exclusively for in-vitro / laboratory research use only | Exclusively for in-vitro / laboratory research use only |
ready to order your compound?
All peptides are supplied in vacuum-sealed lyophilized vials with >99% HPLC purity, certified by independent Mass Spectrometry. Dispatched directly from Spain with zero customs delays across Europe.
semaglutide
Lyophilized vials with verified HPLC purity ≥ 99.0%.
tirzepatide
Lyophilized 10mg and 20mg vials with verified HPLC purity ≥ 99.4%.
Frequently asked questions about Semaglutide vs. Tirzepatide.
Molecular differences, receptor binding profiles, clinical trial benchmarks, reconstitution guidelines, and legal status for laboratory research across Europe.
The core difference lies in receptor targeting. Semaglutide is a single receptor agonist acting solely on GLP-1R. Tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors simultaneously. Concurrent GIP activation amplifies glucose-dependent insulin secretion and enhances adipose tissue metabolic flexibility.
In the SURPASS-2 trial published in The New England Journal of Medicine, Tirzepatide 15 mg outperformed Semaglutide 1 mg across all endpoints: reducing HbA1c by -2.30% (vs -1.86% for Semaglutide) and producing a mean weight loss of -11.2 kg compared to -5.7 kg with Semaglutide, effectively doubling the weight loss magnitude.
Tirzepatide’s GIP component acts synergistically with GLP-1 in hypothalamic satiety circuits and white adipose tissue. It improves adipocyte insulin sensitivity, promotes orderly postprandial lipid buffering, and enhances adipose blood flow, delaying the early plateaus commonly seen with pure GLP-1 monotherapy.
Preclinical studies demonstrate that GIP signaling in the area postrema and solitary tract nucleus counterbalances emetic signals triggered by strong GLP-1R stimulation. This allows Tirzepatide to deliver higher metabolic potency while mitigating the severe nausea associated with escalated GLP-1-only protocols.
Semaglutide exhibits a plasma half-life of approximately 7 days (165 hours) via its C18 fatty diacid at Lys26. Tirzepatide displays a half-life of roughly 5 days (120 hours) supported by a C20 fatty diacid at Lys20. Both structures facilitate once-weekly administration schedules in research models.
Vials should be reconstituted using sterile Bacteriostatic Water (0.9% Benzyl Alcohol), allowing diluent to run gently down the glass wall without vigorous vortexing. Lyophilized vials maintain stability at -20°C for up to 24 months. Once reconstituted, solutions must be kept refrigerated at 2°C–8°C away from light for up to 28 days.
Yes. IberiaLabs stocks high-purity lyophilized Semaglutide (10mg) and Tirzepatide (10mg & 20mg) in Spain, dispatched within 24–72 hours with zero customs checks across the EU.
Both Tirzepatide and related research peptides are 100% legal to purchase, hold, and use for laboratory scientific research, analytical testing, and in-vitro development in Spain and the EU. They are strictly not for direct human consumption or therapeutic medical use.